Home Cart 0 Sign in  

[ CAS No. 170569-87-6 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 170569-87-6
Chemical Structure| 170569-87-6
Structure of 170569-87-6 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 170569-87-6 ]

Related Doc. of [ 170569-87-6 ]

Alternatived Products of [ 170569-87-6 ]

Product Details of [ 170569-87-6 ]

CAS No. :170569-87-6 MDL No. :MFCD03453540
Formula : C16H12F3N3O2S Boiling Point : -
Linear Structure Formula :- InChI Key :MQPLMBSDWYIIID-UHFFFAOYSA-N
M.W : 367.35 Pubchem ID :6426663
Synonyms :
CAY10452;PTPBS
Chemical Name :4-(5-Phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide

Safety of [ 170569-87-6 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 170569-87-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 170569-87-6 ]

[ 170569-87-6 ] Synthesis Path-Downstream   1~19

  • 1
  • [ 326-06-7 ]
  • 4-hydrazinobenzene-1-sulfonamide hydrochloride [ No CAS ]
  • [ 170569-87-6 ]
YieldReaction ConditionsOperation in experiment
77% With hydrogenchloride In N,N-dimethyl acetamide at 20℃; for 24h;
76% With hydrogenchloride In N,N-dimethyl acetamide; water at 23℃; for 24h;
75% In methanol; water at 120℃; for 0.221667h; Flow reactor;
66% In ethanol for 20h; Reflux; 3 General procedure for preparation of compounds 3-5 General procedure: Phenylhydrazine hydrochloride (11 or 12) was added to a stirred solution of the dione (9 or 10) in ethanol (30 mL), and the mixture was refluxed for 20 h. After cooling to room temperature, the reaction mixture was concentrated in vacuo. The resulting residue was dissolved in AcOEt (50 mL) and washed with brine. The organic fraction was dried over Na2SO4 and filtered. The filtrate was concentrated in vacuo and the residue was purified by silica gel chromatography (n-hexane/AcOEt, 2:1) to afford pyrazole compounds 3-5.
33% In ethanol for 20h; Heating;

YieldReaction ConditionsOperation in experiment
75% In methanol; water at 120℃; for 0.221667h; 2 EXAMPLE 1: Synthesis of 4-(5-p-tolyl-3-(trifluoromethyl)-lH-pyrazol-l-yl) benzene sulfonamide (3a, Celecoxib): General procedure: A reactor coil (SS316 tubing id = 1 mm, 10 meter, volume = 8 mL) was assembled and joined to the other components of the continuous flow system to ensure efficient mixing. The stock solution was prepared in a 500 mL volumetric flask under anhydrous condition before injecting into stainless steel 8 mL reactor through a HPLC pump. The stock solution containing a mixture of 4,4,4-trifluoro-l-p-tolylbutane-l,3-dione (2a) (1.0 g, 4.34 mmol, 1.00 equiv) and hydrazinylbenzenesulfonamide hydrochloride (1) (969 mg, 4.34 mmol, 1.00 equiv) in 365 mL of methanol and 35 mL of water was passed through the pre-heated 120 °C SS316-tube reactor (8 mL), keeping 13.3 min. residence time and 32 bar pressure. Finally out-flowing product mixture was quenched and solvent exchange was done from MeOH: water to low boiling solvent diethyl ether by introducing aq. NaOH through an additional X- mixer to form organic-aqueous droplets. Complete extraction between the organic -aqueous segments was observed after 0.5 min retention time achieved by flowing through a PTFE capillary ((id = 1000 qm, length = 2.6 m, vol. = 2 mL). Further, organic-aqueous segment was separated by passing through micro separator of present invention and complete separation was achieved by regulating the back pressures and retention time (5.6 sec) along with the flow rate of diethyl ether (1200 m/min) and aq. NaOH (0.6 m/min). Extracted waste water layer was further extracted with diethyl ether and analyzed by LC-MS, which showed no traces of product and was again confirmed by absence of the corresponding peaks in crude NMR analysis (XH and 13C NMR spectra). The organic extract (diethyl ether layer) was concentrated and the resulting residue was purified by silica gel column chromatography (hexane/ethyl acetate; 60:40) to provide an off-white solid (3a) (411 mg, 85%), Melting point: 152 °C. The spectra data matched with values reported in the literature (Tetrahedron Letters, 54(49), 6682- 6686; 2013; Organic Process Research & Development 2009, 13, 98- 101). (0156) *H NMR (400 MHz, DMSO) d 7.88 (d, / = 8.7 Hz, 2H), 7.57 - 7.53 (m, 2H), 7.52 (s, 2H), 7.22 (d, / = 2.8 Hz, 3H), 7.20 (s, 1H), 2.32 (s, 3H); (0157) 19F NMR (376 MHz, CDCb) d -56.119 (s); (0158) 13C NMR (101 MHz, DMSO) d 145.27, 144.00, 142.18 (q, J = 38.38 Hz), 141.12, 139.11, 129.42, 128.78, 126.81, 126.00, 125.36, 121.18 (q, / = 270.68 Hz), 106.64, 21.30; (0159) IR (Vmax) : 3503, 3357, 3267, 3109, 1601, 1484, 1466, 1409, 1340, 1277, 1238, 1164, 979, 908, 839, 812, 761 cm 1; (0160) HRMS (ESI); m/z calcd for C17H14F3N3O2S [M+H] +: 382.0837, found: 382.0843.
...lar interest consists of compounds and pharmaceutically-acceptable salts thereof as follows: meloxicam (Boehringer Ingelheim); nimesulide (Helsinn); MK-966 (Merck & Co); L-783003 (Merck & Co); T-614 (Toyama); D-1367 (Chiroscience); L-748731 (Merck & Co); L-745337 (Merck & Co); ... 4-(5-(4-chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(5-chloro-2-thienyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-(4-chloro-3,5-diphenyl-1H-pyrazol-1-yl)benzenesulfonamide 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1yl]benzenesulfonamide; ...
A family of specific compounds of particular interest within Formula I consists of compounds, derivatives and pharmaceutically-acceptable salts thereof as follows: 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1yl]benzenesulfonamide; 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[4-chloro-5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide; ...
...cted from compounds, and their pharmaceutically acceptable salts, of the group consisting of meloxicam (Boehringer Ingelheim); nimesulide (Helsinn); MK-966 (Merck & Co); L-783003 (Merck & Co); T-614 (Toyama); D-1367 (Chiroscience); L-748731 (Merck & Co); L-745337 (Merck & Co); ... 4-(5-(4-chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(5-chloro-2-thienyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-(4-chloro-3,5-diphenyl-1H-pyrazol-1-yl)benzenesulfonamide 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-(5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl benzenesulfonamide; 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; ...
A family of specific compounds of particular interest within Formula I consists of compounds, pharmaceutically-acceptable salts and derivatives thereof as follows: 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide; 4-[5(4-fluorophenyl) -3-(trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide; 4-[5-(4-chlorophenyl)-3-((difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[4-chloro-5-(4-chlorophenyl) -3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-((difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; ...
A family of specific compounds of particular interest within Formula II consists of compounds, pharmaceutically-acceptable salts and derivatives thereof as follows: 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; ...
The method of claim 1 wherein the compound is selected from compounds, and their pharmaceutically acceptable salts, selected from the group consisting of 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; ...
A family of specific compounds of particular interest within Formula I consists of compounds, derivatives and pharmaceutically-acceptable salts thereof as follows: 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; ...
The method of claim 8 wherein the compound is selected from compounds, and their pharmaceutically acceptable salts, selected from the group consisting of 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; ...
The method of claim 6 wherein the compound is selected from compounds, and their pharmaceutically acceptable salts, selected from the group consisting of ... 4-(5-(4-chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(5-chloro-2-thienyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-(4-chloro-3,5-diphenyl-1H-pyrazol-1-yl)benzenesulfonamide 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; ...
The method of claim 15 wherein the compound is selected from compounds, and their pharmaceutically acceptable salts, selected from the group consisting of ... 4-(5-(4-chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(5-chloro-2-thienyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-(4-chloro-3,5-diphenyl-1H-pyrazol-1-yl)benzenesulfonamide 4-[(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; ...
The method of claim 2 wherein the compound is selected from compounds, and their pharmaceutically acceptable salts, selected from the group consisting of 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; ...
A family of specific compounds of particular interest within Formula I consists of compounds and pharmaceutically-acceptable salts thereof as follows: ... 4-[4-chloro-3-hydroxymethyl-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide; 4-[4-chloro-5-(4-chlorophenyl)-3-hydroxymethyl-1H-pyrazol-1-yl]benzenesulfonamide; [1-(4-aminosulfonylphenyl)-4-chloro-5-(4-chlorophenyl)-1H-pyrazol-3-yl]propanoic acid; 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-cyanophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(2,4-difluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; ...
A family of specific compounds of particular interest within Formula II consists of compounds and pharmaceutically-acceptable salts thereof as follows: 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[4-chloro-5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide; ...
The method of claim 11 wherein the compounds are selected from compounds, and their pharmaceutically acceptable salts, of the group consisting of 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[4-chloro-5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide; ...
A family of specific compounds of particular interest within Formula I consists of compounds and pharmaceutically-acceptable salts thereof as follows: ... 4-(5-(4-chlorophenyl)-3-(4-nitrophenyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-(5-(4-chlorophenyl)-3-(5-chloro-2-thienyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-(4-chloro-3,5-diphenyl-1H-pyrazol-1-yl)benzenesulfonamide 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; ...
The use of Claim 2 wherein the compound is selected from compounds, and their pharmaceutically acceptable salts, of the group consisting of 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; ...
The use of Claim 7 wherein the compound is selected from compounds, and their pharmaceutically acceptable salts, of the group consisting of 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; ...
Use according to Claim 7 wherein the compound is selected from compounds, and their pharmaceutically acceptable salts, of the group consisting of 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-flucrophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; ...
A family of specific compounds of particular interest within Formula II consists of compounds, pharmaceutically-acceptable salts and derivatives thereof as follows: 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide: 4- [3- (difluoromethyl) -5-(4-methylphenyl) -1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; ...
A family of specific compounds of particular interest within Formula II consists of compounds, pharmaceutically-acceptable salts and derivatives thereof as follows: 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methylphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide; 4-[3-(difluoromethyl)-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide; ...
Use according to Claim 15 wherein the compound is selected from compounds, and their pharmaceutically acceptable salts, of the group consisting of ... 4-(4-chloro-3,5-diphenyl-1H-pyrazol-1-yl)benzenesulfonamide 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; ...
Use according to Claim 1 wherein the compound is selected from compounds, and their pharmaceutically acceptable salts, of the group consisting of 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-chlorophenyl)-3-(difluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; ...
In ethanol for 12h; Reflux; 2 General procedure: Put 1.074g of the product from the previous step into a 250ml round bottom flask equipped with a reflux device,Dissolve in 50ml absolute ethanol, add 1.8g p-hydrazinobenzenesulfonamide hydrochloride,Heat at reflux for 12h (overnight reaction),TLC detection (petroleum ether: ethyl acetate 2:1) after the reaction is complete,Stop heating, stir and cool to room temperature.Filter, collect filter cake and filtrate separately,Use TLC detection (petroleum ether: ethyl acetate 2:1),Most of the product is in the filtrate.Rotate the filtrate to dryness, add 100ml ethyl acetate to dissolve it,Then use deionized water (50ml*3) to wash, separate the organic layer,Add anhydrous sodium sulfate to dry.After re-vaporizing the extract, 1.02 g of the product was obtained.The product was recrystallized using ethanol/water.

  • 3
  • [ 170569-87-6 ]
  • [ 170569-88-7 ]
YieldReaction ConditionsOperation in experiment
1.f Step 2: (1f) 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide mp 168°-169° C.; Anal. calc'd for C16 H11 N3 O2 SF4: C, 49.87; H, 2.88; N, 10.90. Found: C, 49.83; H, 2.89; N, 10.86. (1g) 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide: mp 164°-165° C.; Anal. calc'd for C16 H12 N3 O2 SF3: C, 52.31; H, 3.29; N, 11.43. Found: C, 52.14; H, 3.07; N, 11.34.
  • 4
  • [ 170569-87-6 ]
  • [ 170569-91-2 ]
YieldReaction ConditionsOperation in experiment
1.f Step 2 (1g) 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1yl]benzenesulfonamide: mp 164°-165° C.; Anal. calc'd for C16 H12 N3 O2 SF3: C, 52.31; H, 3.29; N, 11.43. Found: C, 52.14; H, 3.07; N, 11.34. (1h) 4-[5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide: mp 153°-154° C.; Anal. calc'd for C17 H14 N3 O3 SF3: C, 51.38; H, 3.55; N, 10.57. Found: C, 51.00; H, 3.48; N, 10.24.
  • 5
  • [ 326-06-7 ]
  • 4-hydrazinobenzene-1-sulfonamide hydrochloride [ No CAS ]
  • [ 929606-86-0 ]
  • [ 170569-87-6 ]
YieldReaction ConditionsOperation in experiment
With hydrogenchloride In ethanol at 50℃; Title compound not separated from byproducts.;
  • 6
  • [ 58518-08-4 ]
  • [ 4392-54-5 ]
  • [ 170569-87-6 ]
YieldReaction ConditionsOperation in experiment
93% With copper diacetate In dichloromethane for 2.5h; Reflux; regioselective reaction;
  • 7
  • [ 536-74-3 ]
  • [ 170569-87-6 ]
YieldReaction ConditionsOperation in experiment
Multi-step reaction with 2 steps 1.1: n-butyllithium / tetrahydrofuran / 0.5 h / -78 °C 1.2: 1 h 2.1: copper diacetate / dichloromethane / 2.5 h / Reflux
Multi-step reaction with 3 steps 1.1: n-butyllithium / hexane; tetrahydrofuran / -60 - -20 °C / Inert atmosphere 1.2: -60 - 20 °C / Inert atmosphere 2.1: dimethyl sulfoxide / 24 h / 20 °C 3.1: 1,8-diazabicyclo[5.4.0]undec-7-ene / dimethyl sulfoxide / 24 h / 20 °C
  • 8
  • [ 1538-75-6 ]
  • [ 170569-87-6 ]
  • C26H28F3N3O6S [ No CAS ]
YieldReaction ConditionsOperation in experiment
34% With dmap In dichloromethane Reflux;
  • 9
  • [ 326-06-7 ]
  • [ 4392-54-5 ]
  • [ 170569-87-6 ]
YieldReaction ConditionsOperation in experiment
84% With hydrogenchloride; dmap at 20℃;
  • 10
  • C16H12F3N3O2S [ No CAS ]
  • [ 170569-87-6 ]
YieldReaction ConditionsOperation in experiment
297 mg With 1,8-diazabicyclo[5.4.0]undec-7-ene In dimethyl sulfoxide at 20℃; for 24h;
  • 11
  • [ 536-74-3 ]
  • [ 929606-86-0 ]
  • [ 170569-87-6 ]
YieldReaction ConditionsOperation in experiment
Multi-step reaction with 2 steps 1.1: n-butyllithium / hexane; tetrahydrofuran / -60 - -20 °C / Inert atmosphere 1.2: -60 - 20 °C / Inert atmosphere 2.1: 1,8-diazabicyclo[5.4.0]undec-7-ene 2.2: 24 h
  • 12
  • [ 58518-08-4 ]
  • [ 170569-87-6 ]
YieldReaction ConditionsOperation in experiment
Multi-step reaction with 2 steps 1: dimethyl sulfoxide / 24 h / 20 °C 2: 1,8-diazabicyclo[5.4.0]undec-7-ene / dimethyl sulfoxide / 24 h / 20 °C
  • 13
  • [ 58518-08-4 ]
  • 4-hydrazinobenzene-1-sulfonamide hydrochloride [ No CAS ]
  • [ 929606-86-0 ]
  • [ 170569-87-6 ]
YieldReaction ConditionsOperation in experiment
1: 34% 2: 63% Stage #1: 4-hydrazinobenzene-1-sulfonamide hydrochloride With 1,8-diazabicyclo[5.4.0]undec-7-ene Stage #2: 1,1,1-trifluoro-4-phenylbut-3-yn-2-one for 24h; regioselective reaction;
  • 14
  • [ 170569-87-6 ]
  • [ 169590-42-5 ]
YieldReaction ConditionsOperation in experiment
Multi-step reaction with 2 steps 1: C20H28N4O2Pd(2+)*2BF4(1-); tris(2,2-bipyridine)ruthenium(II) hexafluorophosphate / acetonitrile / 22 h / 40 °C / Sealed tube 2: 1-methyl-pyrrolidin-2-one; bis(tricyclohexylphosphine)nickel(II) dichloride; tetrabutyl-ammonium chloride / tetrahydrofuran / 20 h / 50 °C / Sealed tube
  • 15
  • 1-fluoro-4-methyl-1,4-diazoniabicyclo<2.2.2>octane ditetrafluoroborate [ No CAS ]
  • [ 170569-87-6 ]
  • C23H26F3N5O2S(2+)*2BF4(1-) [ No CAS ]
YieldReaction ConditionsOperation in experiment
52% With tris(2,2-bipyridine)ruthenium(II) hexafluorophosphate; C20H28N4O2Pd(2+)*2BF4(1-) In acetonitrile at 40℃; for 22h; Sealed tube;
  • 16
  • [ 170569-87-6 ]
  • C17H14F3N3O5S2 [ No CAS ]
  • C17H14F3N3O5S2 [ No CAS ]
  • C17H14F3N3O5S2 [ No CAS ]
YieldReaction ConditionsOperation in experiment
1: 38 %Spectr. 2: 13 %Spectr. 3: 6 %Spectr. With bis(methanesulfonyl)peroxide at 23℃; for 16h; Inert atmosphere; Schlenk technique; Overall yield = 57 %; Overall yield = 721 mg;
  • 17
  • [ 170569-87-6 ]
  • 4-(4-Hydroxy-5-phenyl-3-trifluoromethyl-pyrazol-1-yl)-benzenesulfonamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
Multi-step reaction with 2 steps 1: bis(methanesulfonyl)peroxide / 16 h / 23 °C / Inert atmosphere; Schlenk technique 2: lithium diisopropyl amide / tetrahydrofuran / 0.5 h / -78 °C / Inert atmosphere; Schlenk technique
  • 18
  • [ 98-86-2 ]
  • [ 170569-87-6 ]
YieldReaction ConditionsOperation in experiment
Multi-step reaction with 2 steps 1.1: sodium hydride / tetrahydrofuran / 0.5 h / 0 °C 1.2: 12 h / 0 - 25 °C 2.1: methanol; water / 0.22 h / 120 °C / 24002.4 Torr / Flow reactor
  • 19
  • [ 63-74-1 ]
  • [ 170569-87-6 ]
YieldReaction ConditionsOperation in experiment
Multi-step reaction with 2 steps 1.1: sodium nitrite; hydrogenchloride / water / 0.25 h / Cooling with ice 1.2: 1 h / 0 °C 2.1: methanol; water / 0.22 h / 120 °C / 24002.4 Torr / Flow reactor
Same Skeleton Products
Historical Records